₩8,460.00 ($6.30)

-210.00 (-2.42%)

Weekly Expected Move ±4.6%

₩7685 ₩8072 ₩8460 ₩8848 ₩9235

KOE · Healthcare · Biotechnology · Tech Score Buy · Power 56 · ₩782.6B mcap · 69M float · 0.506% daily turnover

Revenue

$1.27T +21.4% ▲

5Y CAGR: +13.8%

Gross Profit

$324.5B +17.9% ▲

5Y CAGR: +12.6%

Operating Income

-$57.1B +4.3% ▲

Net Income

-$109.9B -1264.3% ▼

EPS (Diluted)

$-1636.98 -1039.0% ▼

EBITDA

-$854M -101.1% ▼

View Full Income Statement

Line Item	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$727.5B	$844.6B	$954.0B	$1.05T	$1.27T
YoY Growth	+9.4%	+16.1%	+12.9%	+9.5%	+21.4%
Cost of Revenue	$522.6B	$655.4B	$677.6B	$769.8B	$943.8B
Gross Profit	$204.9B	$189.2B	$276.4B	$275.3B	$324.5B
Gross Margin	28.2%	22.4%	29.0%	26.3%	25.6%
R&D Expenses	$13.0B	$14.4B	$14.6B	$16.0B	$24.6B
SG&A Expenses	$89.2B	$104.4B	$122.7B	$147.9B	$341.1B
Operating Expenses	$198.5B	$242.8B	$285.9B	$334.9B	$381.6B
Operating Income	$6.4B	-$53.7B	-$9.4B	-$59.7B	-$57.1B
Operating Margin	0.9%	-6.4%	-1.0%	-5.7%	-4.5%
Interest Expense	$14.5B	$20.9B	$2.2B	$37.2B	$54.8B
Income Before Tax	-$11.5B	-$70.5B	$3.2B	-$6.2B	-$143.3B
Tax Expense	$11.8B	-$1.6B	$8.7B	$8.3B	$3.4B
Net Income	-$14.0B	-$47.5B	-$8.4B	-$8.1B	-$109.9B
Net Margin	-1.9%	-5.6%	-0.9%	-0.8%	-8.7%
EPS (Diluted)	$-256.29	$-844.95	$-147.73	$-143.72	$-1636.98
EBITDA	$30.5B	-$17.7B	$70.1B	$76.0B	-$854M
Shares Outstanding	55M	56M	57M	59M	67M

Line Item	FY2024 Q3	FY2024 Q4	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4	FY2026 Q1	FY2026 Q2
Revenue	$272.0B	$276.0B	$304.1B	$298.9B	$318.7B	$346.5B	$329.7B	$316.4B
Cost of Revenue	$197.0B	$206.7B	$218.5B	$217.6B	$225.9B	$250.9B	$251.8B	$240.2B
Gross Profit	$75.1B	$69.3B	$85.7B	$81.3B	$92.8B	$95.7B	$77.9B	$76.3B
Gross Margin	27.6%	25.1%	28.2%	27.2%	29.1%	27.6%	23.6%	24.1%
R&D Expenses	$3.5B	$5.0B	$0	$6.0B	$5.5B	$8.6B	$5.5B	$4.1B
SG&A Expenses	$36.0B	$50.1B	$98.2B	$47.1B	$47.0B	$90.6B	$54.4B	$55.8B
Operating Expenses	$81.9B	$108.8B	$98.2B	$102.1B	$100.8B	$103.8B	$108.5B	$104.5B
Operating Income	-$6.8B	-$39.5B	-$12.5B	-$20.8B	-$8.1B	-$8.1B	-$30.5B	-$28.2B
Operating Margin	-2.5%	-14.3%	-4.1%	-6.9%	-2.5%	-2.3%	-9.3%	-8.9%
Interest Expense	$9.4B	$12.7B	$13.8B	$13.9B	$13.1B	$14.1B	$13.8B	$12.6B
Income Before Tax	$23.5B	-$25.6B	-$24.0B	-$77.1B	-$9.0B	-$33.2B	$86M	$45.9B
Tax Expense	$3.2B	$3.5B	$3.0B	-$1.8B	$145M	$2.1B	$2.7B	$15.2B
Net Income	$26.0B	-$22.2B	-$20.8B	-$58.5B	-$11.8B	-$18.8B	$15.6B	$29.3B
Net Margin	9.6%	-8.0%	-6.8%	-19.6%	-3.7%	-5.4%	4.7%	9.2%
EPS (Diluted)	$464.00	$-393.71	$-341.04	$-982.00	$-163.00	$-237.10	$150.24	$115.26
EBITDA	$44.0B	$1.3B	$100.2B	-$48.9B	$18.5B	$5.0B	-$15.2B	-$13.8B
Shares Outstanding	56M	56M	61M	60M	72M	79M	91M	101M

085660.KQ KOE